^
    Back
    Association details:
    Biomarker:EEF2K overexpression
    Cancer:Melanoma
    Drug Class:PD1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Immunother Cancer
    Title:

    eEF2K promotes PD-L1 stabilization through inactivating GSK3ß in melanoma

    Excerpt:
    In this study, we used a cohort of 38 patients with melanoma who received anti-PD-1 treatment to explore the association between eEF2K expression and immunotherapy efficacy against melanoma. High eEF2K expression is correlated with better therapeutic response and longer survival in patients with melanoma treated with PD-1 monoclonal antibody (mAb).
    DOI:
    10.1136/jitc-2021-004026